TaiMed Biologics (ROCO:4147) Total Stockholders Equity : NT$4,212.2 Mil (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is TaiMed Biologics Total Stockholders Equity?

TaiMed Biologics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was NT$4,212.2 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. TaiMed Biologics's Book Value per Share for the quarter that ended in Mar. 2024 was NT$15.42. The ratio of a company's debt over equity can be used to measure how leveraged this company is. TaiMed Biologics's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.18.

TaiMed Biologics Total Stockholders Equity Historical Data

The historical data trend for TaiMed Biologics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TaiMed Biologics Total Stockholders Equity Chart

TaiMed Biologics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

3,586.40

3,415.88

2,941.50

2,714.92

2,566.09

TaiMed Biologics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															2,644.66	2,646.83	2,643.93	2,566.09	4,212.17

TaiMed Biologics (ROCO:4147) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

TaiMed Biologics's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(4212.168	-	0)	/	273.079
	=	15.42

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

TaiMed Biologics's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(229.292	+	514.329)	/	4212.168
	=	0.18

TaiMed Biologics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of TaiMed Biologics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

TaiMed Biologics (ROCO:4147) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TaiMed Biologics Inc (ROCO:4147) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 607, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN, 11492

Website

http://www.taimedbiologics.com

TaiMed Biologics Inc is a Taiwan-based biotechnology company. It is engaged in the discovery, development, and delivery of medicines for infectious disease. It capitalizes on its intellectual, extensive expertise, and management resources to develop a health-care product pipeline that benefits patients, rewards investors, and propels to prominence in the biotechnology industry. The company's products pipeline includes TMB-365, VRC07-523LS, and others.

TaiMed Biologics (ROCO:4147) Headlines

No Headlines